Skip to main content
Cyber Week Sale - Get 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

COSCIENS (TSX: CSCI) Gives Wuzhou Macrilen Rights, Ten-Year Term, €800,000 Order

Wuzhou gains exclusive rights to register, import, and commercialize Macrilen® for Adult Growth Hormone Deficiency in the Greater Bay Area and Singapore under a 10-year deal.

Summary by stocktitan.net
Exclusive deal makes Wuzhou register, import and commercialize Macrilen for AGHD patients in Hong Kong, Macao, Singapore, Guangdong and Hainan.

10 Articles

Globe NewswireGlobe Newswire
+9 Reposted by 9 other sources
Center

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life sciences...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 63% of the sources lean Left
63% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Hamilton Spectator broke the news in Hamilton, Canada on Monday, December 1, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Toronto, ON icon

Toronto, ON

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal